Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01032109
Recruitment Status : Completed
First Posted : December 15, 2009
Last Update Posted : February 26, 2016
Information provided by (Responsible Party):
Takahiro Kawaji, Kumamoto University

Brief Summary:
The purpose of this study is to compare 12-month results of two single initial treatments—photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab—for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

Condition or disease Intervention/treatment Phase
Age-related Macular Degeneration Drug: Bevacizumab Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Verteporfin Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration
Study Start Date : October 2006
Actual Primary Completion Date : May 2008
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Bevacizumab Drug: Bevacizumab
A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
Other Name: Avastin

Primary Outcome Measures :
  1. Visual acuity [ Time Frame: The comparison between baseline and 12-month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • choroidal neovascularization caused by age-related macula degeneration
  • no previous treatment
  • a follow-up at least 12 months
  • a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart

Exclusion Criteria:

  • choroidal neovascularization caused by other eye diseases
  • ocular surgery within the past 3 mouths
  • history of uveitis
  • intraocular pressure higher than 25 mmHg, or glaucoma
  • history of systemic or ocular thromboembolic events.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01032109

Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan, 860-8556
Sponsors and Collaborators
Kumamoto University
Principal Investigator: Takahiro Kawaji, MD, PhD Department of Ophthalmology, Kumamoto University Graduate School & Medical Sciences

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Takahiro Kawaji, Associate Professor, Kumamoto University Identifier: NCT01032109     History of Changes
Other Study ID Numbers: PCBK610
First Posted: December 15, 2009    Key Record Dates
Last Update Posted: February 26, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents